References
1. Scallan E., Hoekstra R.M., Angulo F.J., et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis. 2011; 17 (1): 7-15. DOI: https://doi.org/10.3201/eid1701.p11101
2. Decree of the Chief State Sanitary Doctor of the Russian Federation dated January 28, 2021 N 4 “On approval of sanitary rules and norms SanPiN 3.3686-21 “Sanitary and epidemiological requirements for the prevention of infectious diseases". URL: https:// docs.cntd.ru/document/ 573660140 (date of access: November 13, 2021). (in Russian)
3. de Noordhout C.M., Devleesschauwer B., Angulo F.J., et al. The global burden of listeriosis: a systematic review and meta-analysis. Lancet Infect Dis. 2014; 14 (11): 1073-82. DOI: https://doi.org/10.1016/S1473-3099(14)70870-9; PMID: 25241232.
4. Charlier C., Disson O., Lecuit M. Maternal-neonatal listeriosis. Virulence. 2020; 11 (1): 391-7. DOI: https://doi.org/10.1080/21505594.2020.1759287
5. Elinav H., Hershko-Klement A., Valinsky L. et al. Israeli Listeria Study Group. Pregnancy-associated listeriosis: clinical characteristics and geospatial analysis of a 10-year period in Israel. Clin Infect Dis. 2014; 59 (7): 953-61. DOI: https://doi.org/10.1093/cid/ciu504; PMID: 24973315.
6. Lamont R.F., Sobel J., Mazaki-Tovi S., et al. Listeriosis in human pregnancy: a systematic review. J Perinat Med. 2011; 39 (3): 227-36. DOI: https://doi.org/10.1515/jpm.2011.035; PMID: 21517700.
7. Craig A.M., Dotters-Katz S.., Kuller J.A., et al. Listeriosis in pregnancy: a review. Obstet. Gynecol. Surv. 2019; 74 (6): 362-368. DOI: https://doi.org/10.1097/OGX.0000000000000683; PMID: 31216045.
8. Shishov A.S., Klimova E.A., Karetkina G.N., et al. Antibacterial therapy of lysterious lesions of the central nervous system in real clinical practice. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 (2): 77-83. DOI: https://doi.org/10.33029/2305-3496-2020-9-2-77-83 (in Russian)
9. Voronina O.L., Kunda M.S., Ryzhova N.N., et al. Listeriosis: genotyping as a key for identification a possible source of infection. Kliniceskaa Mikrobiologia i Antimi-krobnaa Himioterapia [Clinical Microbiology and Antimicrobial Chemotherapy]. 2019; 21 (4): 261-73. DOI: https://doi.org/10.36488/cmac.2019A261273 (in Russian)
10. Voronina O.L., Kunda M.S., Ryzhova N.N., et al. Regularities of the ubiquitous polyhostal microorganisms selection by the example of three taxa. Molekulyarnaya biologiya [Molecular Biology]. 2015, 49 (3): 380-90. DOI: https://doi.org/10.1134/S0026893315030176 (in Russian)
11. Voronina O.L., Tartakovsky I.S., Yuyshchuk N.D., et al. Analysis of sporadic cases of invasivelisteriosis in a metropolis. Journal of microbiology, epidemiology and immunobiology [Zhurnal Mikrobiologii, Ёpidemiologii i Immunobiologii]. 2020; 97 (6): 547-55. DOI: https://doi.org/10.36233/0372-9311-2020-97-6-3 (in Russian)
12. WHO. Listeriosis. Available at: www.who.int/newsroom/factsheets/detail/listeriosis
13. CDC. Listeria (Listeriosis). Available at: https://www.cdc.gov/listeria/risk.html
14. Vaillant V., de Valk H., Baron E., et al. Foodborne infections in France. Foodborne Pathog Dis. 2005; 2 (3): 221-32. DOI: https://doi.org/10.1089/fpd.2005.2.221; PMID: 16156703.
15. Charlier C., Perrodeau E., Leclercq A., et al. M. s. group. Clinical features and prognostic factors of listeriosis: The MONALISA national prospective cohort study. Lancet Infect Dis. 2017; 17 (5): 510-9. DOI: https://doi.org/10.1016/S1473-3099(16)30521-7
16. Wadhwa Desai R., Smith M.A. Pregnancy-related listeriosis. Birth Defects Res. 2017; 109 (5): 324-35. DOI: https://doi.org/10.1002/bdr2.1012
17. Madjunkov M., Chaudhry S., Ito S. Listeriosis during pregnancy. Arch Gynecol Obstet. 2017; 296 (2): 143-52. DOI: https://doi.org/10.1007/s00404-017-4401-1
18. Wang Z., Tao X., Liu S., et al. An update review on Listeria infection in pregnancy. Infect Drug Resist. 2021; 14: 1967-78. DOI: https://doi.org/10.2147/IDR.S313675
19. Cimolai N. A comprehensive analysis of maternal and newborn disease and related control for COVID-19. SN Compr Clin Med. 2021: 1-23. DOI: https://doi.org/10.1007/s42399-021-00836-0
20. Bengoechea J.A., Bamford C.G. SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO Mol Med. 2020; 12 (7): e12560. DOI: https://doi.org/10.15252/emmm.202012560
21. Morris D.E., Cleary D.W., Clarke S.C. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017; 8: 1041. DOI: https://doi.org/10.3389/fmicb.2017.01041
22. Chen X., Liao B., Cheng L., et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020; 104 (18): 7777-85. DOI: https://doi.org/10.1007/s00253-020-10814-6
23. Bortell N., Aguilera E.R., Lenz L.L. Pulmonary insults exacerbate susceptibility to oral Listeria monocytogenes infection through the production of IL-10 by NK cells. PLoS Pathog. 2021; 17 (4): e1009531. DOI: https://doi.org/10.1371/journal.ppat.1009531
24. Mirzaei R., Goodarzi P., Asadi M., et al. Bacterial co-infections with SARS-CoV-2. IUBMB Life. 2020; 72 (10): 2097-111. DOI: https://doi.org/10.1002/iub.2356
25. Foldvari-Nagy L., Schnabel T., Dornyei G., et al. On the role of bacterial metal-loproteases in COVID-19 associated cytokine storm. Cell Commun Signal. 2021; 19 (1): 7. DOI: https://doi.org/10.1186/s12964-020-00699-3
26. Wang L., He W., Yu X., et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020; 80 (6): 639-45. DOI: https://doi.org/10.1016/j.jinf.2020.03.019
27. Drevets D.A., Bronze M.S. Listeria monocytogenes: epidemiology, human disease, and mechanisms of brain invasion. FEMS Immunol Med Microbiol. 2008; 53 (2): 151-65. DOI: https://doi.org/10.1111/j.1574-695X.2008.00404.x
28. Tay M.Z., Poh C.M., Renia L., et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20 (6): 363-74. DOI: https://doi.org/10.1038/s41577-020-0311-8
29. Alcock J., Masters A. Cytokine storms, evolution and COVID-19. Evol Med Public Health. 2021; 9 (1): 83-92. DOI: https://doi.org/10.1093/emph/eoab005
30. Meira F., Moreno-Garcia E., Linares L., et al. Impact of inflammatory response modifiers on the incidence of hospital-acquired infections in patients with COVID-19. Infect Dis Ther. 2021; 1-12. DOI: https://doi.org/10.1007/s40121-021-00477-9
31. Du P., Geng J., Wang F., et al. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci. 2021; 18 (6): 1356-62. DOI: https://doi.org/10.7150/ijms.53564
32. Cellina M., Fetoni V., Baron P., et al. Listeria meningoencephalitis in a patient with rheumatoid arthritis on anti-Interleukin 6 receptor antibody tocilizumab. J Clin Rheumatol. 2015; 21 (6): 330. DOI: https://doi.org/10.1097/RHU.0000000000000287
33. Bodro M., Paterson D.L. Listeriosis in patients receiving biologic therapies. Eur J Clin Microbiol Infect Dis. 2013; 32 (9): 1225-30. DOI: https://doi.org/10.1007/s10096-013-1873-1
34. Somers E.C., Eschenauer G.A., Troost J.P., et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021; 73 (2): e445-54. DOI: https://doi.org/10.1093/cid/ciaa954
35. Kimmig L.M., Wu D., Gold M., et al. IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020; 7: 583897. DOI: https://doi.org/10.3389/fmed.2020.583897
36. Komura T., Ohta H., Nakai R., et al. Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab. Intern Med. 2016; 55 (14): 1923-7. DOI: https://doi.org/10.2169/internalmedicine.55.5981
37. Watanabe E., Sugawara H., Yamashita T., et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still’s disease: a case-based review. Case Rep Med. 2016; 2016: 5656320. DOI: https://doi.org/10.1155/2016/5656320
38. Bradshaw M.J., Cho T.A., Chow F.C. Central nervous system infections associated with immunosuppressive therapy for rheumatic disease. Rheum Dis Clin North Am. 2017; 43 (4): 607-19. DOI: https://doi.org/10.1016Zj.rdc.2017.06.009
39. Gudiol C., Dura-Miralles X., Aguilar-Company J., et al. Co-infections and superinfections complicating COVID-19 in cancer patients: a multicentre, international study. J Infect. 2021; 83 (3): 306-13. DOI: https://doi.org/10.1016/jjinf.2021.07.014